PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research ...
The Philadelphia Flyers officially sign Leo Carlsson to an offer sheet that would give him the league's highest AAV.
Three of 5 (60%) patients on the LoVAS regimen relapsed compared with 2 of 16 (12.5%) on the PEXIVAS regimen. In most cases, relapses occurred early after treatment initiation.
To design safe clinical trials, it is crucial to better understand and predict gene editing outcomes in preclinical studies. Bence György and collaborators have shown that adeno-associated viruses ...
In recent years, adeno-associated virus (AAV) has been recognized as the leading vehicle (vector) for in vivo delivery of therapeutic genes because it is non-pathogenic and efficiently targets many ...
Several quality attributes (QAs) must be monitored to ensure an effective and safe final product when developing adeno-associated virus (AAV) vectors as drug products. Thermal stability, aggregate ...
AskBio founder R. Jude Samulski talks about the evolution and future of AAV gene therapy following his company’s blockbuster acquisition by Bayer in 2020. R. Jude Samulski, PhD It is rare that a ...
SB Nation on MSN
Devils Re-Sign Nico Hischier to a 5-Year, $11.7M AAV contract
The Devils got their most important piece of offseason business done, agreeing to a new contract with Nico Hischier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results